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Summary
Background.  —  Many  stents  are  used  ‘‘off-label’’  during  the  management  of  congenital  heart
diseases (CHD).
Aims.  —  To  describe  indications  for,  results  of,  and  adverse  events  associated  with  stenting  in
CHD in  current  practice.
Methods.  —  Participation  in  this  study  was  proposed  to  all  catheterization  laboratories  that
specialize in  CHD  in  France  (M3C  network).  All  paediatric  and  adult  CHD  cases  with  stent
implantation  in  2013  were  included  retrospectively.
Results.  —  Overall,  207  stents  were  implanted  in  151  patients  across  11  centres.  Median  age  was
13.7 years  (range,  5  days  to  70.1  years).  Main  procedure  indications  were  branch  pulmonary
artery angioplasty  (n  =  46,  29.1%),  aortic  (re)coarctation  stenting  (n  =  43,  27.2%),  percutaneous
pulmonary  valve  implantation  (n  =  32,  20.2%)  and  ductus  arteriosus  stenting  (n  =  14,  8.9%).  The
main stents  implanted  were  the  CP  StentTM (n  =  61,  29.5%),  the  MaxTM LD  stent  (n  =  43,  20.8%),
the Valeo® stent  (n  =  28,  13.5%)  and  valved  stents  (n  =  30,  14.5%).  Procedures  were  considered
successful  in  96.8%  of  cases  (95%  conﬁdence  interval  [CI]  92.8—99.0%).  Adverse  events  were
observed in  23  procedures  (14.7%,  95%  CI  9.5—21.0%).  Ductus  arteriosus  stenting  (odds  ratio
12.4, 95%  CI  2.0—77.5;  P  <  0.01)  and  pulmonary  revalvulation  (odds  ratio  5.9,  95%  CI  1.1—32.3;
P =  0.04)  were  risk  markers  for  stent-related  adverse  events.
Conclusions.  —  Stents  are  used  in  various  CHD  catheterization  procedures,  from  infancy  to  adult
age. The  adverse  events  rate  is  signiﬁcant  and  is  related  to  the  type  of  procedure.
© 2015  Published  by  Elsevier  Masson  SAS.
MOTS  CLÉS
Stent  congenital  ;
Cardiopathies
congénitales  ;
Cardiologie
pédiatrique  ;
Stent  biorésorbable  ;
Revalvulation
pulmonaire
percutanée
Résumé
Contexte.  —  De  nombreux  stents  sont  utilisés  off-label  pour  le  traitement  interventionnel  des
cardiopathies  congénitales.
Objectifs.  —  L’objectif  principal  de  cette  étude  est  de  décrire  les  indications,  les  résultats  et  les
événements  indésirables  des  stents  implantés  pour  le  traitement  des  cardiopathies  congénitales
en pratique  courante.
Méthodes.  —  La  participation  à  cette  étude  a  été  proposée  à  tous  les  centres  franc¸ais  de  cardio-
logie interventionnelle  pédiatrique  et  congénitale  (réseau  M3C).  Parmi  11  centres  participants,
tous les  procédures  avec  stents,  sur  une  année  en  2013  ont  été  analysés  rétrospectivement.
Résultats.  —  Deux  cents  sept  stents  ont  été  implantés  chez  151  patients.  L’âge  médian  était
de 13,7  ans  (min  :  5  jours  ;  max  :  70,1  ans).  Les  indications  principales  des  procédures  étaient
l’angioplastie  des  branches  pulmonaires  (n  =  46,  29,1  %),  l’angioplastie  de  l’isthme  aortique
(n =  43,  27,2  %),  la  revalvulation  pulmonaire  percutanée  (n  =  32,  20,2  %),  et  le  stenting  de
canal artériel  (n  =  14,  8,9  %).  Les  principaux  stents  utilisés  étaint  le  CP  StentTM (n  =  61,  29,5  %),
l’eV3 MaxTM LD  (n  =  43,  20,8  %),  le  Valeo® (n  =  28,  13,5  %)  et  les  stents  valvés  (n  =  30,  14,5  %).
Les procédures  ont  été  réussies  dans  96,8  %  (IC  95  %  92,8—99,0  %).  Des  événements  indésirables
ont été  observés  dans  23  procédures  (14,7  %,  IC  95  %  9,5—21,0  %).  Le  stenting  du  canal  artériel
(OR 12,4,  IC  95  %  2,0—77,5  ;  p  <  0,01)  et  la  revalvulation  pulmonaire  (OR  5,9,  IC  95  %  1,1—32,3  ;
p =  0,04)  étaient  des  marqueurs  de  risque  de  complications  reliées  au  stent.
Conclusion.  —  Les  stents  sont  utilisés  dans  de  multiples  procédures  du  cathétérisme  interven-
tionnel des  cardiopathies  congénitales,  de  l’enfance  à  l’âge  adulte.  Le  risque  de  complications
est signiﬁcatif  et  semble  relié  au  type  de  procédure.
© 2015  Publié  par  Elsevier  Masson  SAS.
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age  was  13.7  years  (range,  5  days  to  70.1  years).  Nineteen
patients  (12.6%)  were  aged  under  1  year  and  41  (27.2%)  were52  
ackground
ince  the  ﬁrst  report  of  transcatheter  balloon  dilation  of
ulmonary  stenosis  in  1953  [1],  balloon  angioplasty  has
een  widely  used  for  many  valvular  and  vascular  congeni-
al  lesions  [2—5].  However,  ineffective  relief  of  obstruction
nd  vessel  damage  has  been  observed  [3—5].  A  ‘‘stent’’  is
 tubular  meshed  endoprosthesis  that  has  contributed  to
vercome  some  of  these  issues,  whether  in  acquired  or  con-
enital  lesions  [4,6—8].  We  recently  published  an  extended
eview  of  stent  types  and  indications  in  the  treatment  of
ongenital  heart  diseases  (CHD)  [9].  However,  we  were
nable  to  describe  the  distribution  of  indications  and  stents
sed  in  current  practice.  Moreover,  new  stents  are  available
10—12],  but  few  devices  are  authorized  for  use  in  congen-
tal  heart  lesions,  and  many  stents  are  currently  implanted
n  ‘‘off-label’’  indications.  As  the  ﬁeld  of  congenital  and
nterventional  cardiology  is  rapidly  evolving,  the  safety  and
fﬁciency  of  these  procedures  have  to  be  investigated.  In
his  French  multicentre  study,  we  aimed  to  describe  the  cur-
ent  types  of  stents  used  to  treat  congenital  heart  lesions,
ssess  the  indications  for  these  procedures,  evaluate  their
fﬁciency,  and  underline  early  complications  after  stenting
nd  associated  risk  factors.
ethods
articipation  in  this  retrospective  observational  multicentre
tudy  was  proposed  on  a  voluntary  basis  to  all  catheteriza-
ion  laboratories  that  specialize  in  the  treatment  of  CHD
n  France  (M3C  network).  Finally,  11  centres  agreed  to
articipate.  All  catheterization  procedures  involving  stent
mplantation  in  children  or  adults  with  CHD  performed
n  these  centres  between  January  2013  and  December
013  were  reviewed.  Procedures  with  stent  implantation  in
eripheral  vascular  lesions  or  in  renal  arteries  in  children
ere  excluded.  Hybrid  procedures  with  stent  implanta-
ion  during  cardiac  surgery  were  included.  Catheterizations
ere  performed  by  paediatric  cardiologists  specialized
n  the  interventional  treatment  of  CHD.  In  three  cen-
res  with  less  experience  in  stenting,  procedures  were
erformed  in  partnership  with  an  expert  from  another
entre.
Stenting  procedures  were  performed  according  to  oper-
tor  and  institutional  practice.  Variables  collected  included
emographic  data  (age,  weight  and  height),  clinical  data
diagnosis,  catheterization  indication),  procedural  data
type,  diameter  and  localization  of  stents  implanted,  and
esults)  and  early  complications.  Early  complications  were
eﬁned  as  complications  occurring  during  the  initial  stenting
rocedure,  during  the  index  hospitalization  or  during  the
rst  30  days  after  the  procedure.  CHD  were  characterized
ccording  to  the  ‘‘anatomical  and  clinical  classiﬁcation  of
ongenital  heart  defects  (ACC-CHD)’’  for  the  main  diagno-
is  [13].  The  indication  for  stent  implantation  was  collected
nd  classiﬁed  as  follows  [9]:  stenting  to  increase  the  efﬁ-
iency  of  balloon  angioplasty;  stenting  to  increase  the  safety
f  balloon  angioplasty;  stenting  to  occlude  a  shunt;  sten-
ing  to  maintain  shunt  patency;  or  stenting  as  a  support  for
ercutaneous  valve  replacement.
a
F
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Stents  were  classiﬁed  according  to  their  diameter
t  the  implantation  site,  as  previously  described:  small
3—6  mm),  medium  (7—11  mm),  large  (12—17  mm),  extra-
arge  (18—25  mm)  and  extra-extra-large  (>  25  mm)  [14].
tent  implantation  was  considered  successful  when  the  fol-
owing  criteria  were  met:  if  the  stent  was  implanted  and
table  in  the  target  localization  and  if  the  stent  fulﬁlled  its
ain  objective  (no  signiﬁcant  residual  gradient  if  the  indi-
ation  was  to  relieve  an  obstruction;  no  parietal  lesion  for
 safety  indication;  no  residual  shunting  if  the  indication
as  to  occlude  a  shunt;  shunt  patency  if  it  was  the  main
bjective;  successful  valved  stent  implantation).
Procedural  and  30  days  post-procedure  adverse  events
ere  classiﬁed  according  to  the  Congenital  Cardiac
atheterization  Project  (C3PO)  [15].
The  term  ‘‘adverse  events’’  was  inclusive  of  all  adverse
vents  from  severity  levels  1  to  5.  High-severity  adverse
vents  were  deﬁned  as  any  level  3,  4  or  5  adverse  events.
f  stent  implantation  was  the  most  likely  cause  leading  to
 complication,  the  latter  was  recorded  as  a  stent-related
dverse  event.  Each  procedure  with  an  adverse  event  was
eviewed  by  the  main  investigator  and  local  investigators.
he  study  database  was  registered  and  approved  by  the
ational  Commission  for  Data  Processing  and  Freedoms  (no
809711  v  0).
tatistical analysis
tatistical  analysis  was  performed  using  Stata® 11.2  soft-
are  (StataCorp,  College  Station,  TX,  USA).  Quantitative
easurements  are  expressed  as  medians  with  interquar-
ile  ranges  and  minimal  and  maximal  values.  Qualitative
ata  are  expressed  as  counts  and  percentages.  A  descrip-
ive  analysis  of  demographic  data,  pathology,  stent  types,
tent  indications  and  adverse  events  was  performed,  dis-
laying  percentages  and  95%  conﬁdence  intervals  (CIs).
otential  determinants  of  outcome  were  then  investigated
hrough  a  logistic  regression  analysis,  including  all  pro-
edures.  Outcome  measures  were  all  procedural  adverse
vents,  stent-related  adverse  events,  and  high-severity
dverse  events.  The  following  variables  were  incorporated
eparately  into  the  model:  operator,  centre,  age,  weight,
enetic  syndrome,  stent  type,  stent  size  and  procedure
ype.  Unadjusted  odd  ratios,  their  95%  CIs  and  P  values  are
eported.  The  model,  including  the  procedure  type,  was
orced  with  the  operator  variable  to  account  for  its  effect.
djusted  odd  ratios  (ORs)  are  reported.  A P  value  <  0.05  was
onsidered  to  be  signiﬁcant.
esults
 total  of  207  stents  were  implanted  during  158  procedures
n  151  patients  across  11  centres.  The  patients’  medianged  over  18  years.  The  main  diagnoses  were  tetralogy  of
allot  and  variants  (n  =  55,  36.7%)  and  aortic  (re)coarctation
n  = 40,  26.5%).  Demographic  data  and  procedure  types  are
etailed  in  Table  1.
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Table  1  Population  description.
Demographic  data
Age  (years)  13.7  (6.5—21.7)  [5  days;  70.1  years]
Age  ≤  1  month  15  (9.9)
Age  >  18  years  41  (27.2)
Weight  (kg) 45.0  (18.7—62.0)  [2.7;  97.0]
Weight  ≤  5  kg  16  (10.7)
Weight  ≤  20  kg  39  (26.0)
Genetic  syndrome  9  (4.9)
Procedure  type  (n  =  158)
Stenting  coarctation  (n  =  28);  recoarctation  (n  =  15)  43  (27.2)
PA  stenosis  (n  =  46);  thrombosis  (n  =  1)  47  (29.7)
PPVI  32  (20.2)
RV-to-PA  conduit  stenting  10  (6.3)
DA  stenting  14  (8.9)
BT  shunt  stenosis  (n  =  1);  thrombosis  (n  =  2)  3  (1.9)
Coronary  lesions  3  (1.9)
Mustard  bafﬂe  stenosis;  vena  cava  stenosis 2  (1.3)
Potts  shunt  occlusion 1 (0.6)
Cavopulmonary  conduit  stenosis  (n  =  1);  fenestration  occlusion  (n  =  2) 3  (1.9)
TTVI  1  (0.6)
Data are expressed as median (interquartile range) [minimum; maximum] or number (%). BT: Blalock-Taussig; DA: ductus arteriosus;
PA: pulmonary artery; RV: right ventricle; PPVI: percutaneous pulmonary valve implantation; TTVI: transcatheter tricuspid valve
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Stenting indications
Stents  were  used  to  increase  the  efﬁcacy  of  balloon  dilation
(n  =  87,  42.0%),  as  part  of  percutaneous  valve  implanta-
tion  (n  =  60,  29.0%),  for  a  safety  reason  (n  =  32,  15.5%),
to  maintain  shunt  patency  (n  =  20,  9.7%)  or  to  close  shunt
patency  (n  =  3,  1.4%)  (Fig.  1  and  Fig.  2).  Main  indications
were  branch  pulmonary  artery  angioplasty  (n  =  46,  29.1%),
aortic  (re)coarctation  stenting  (n  =  43,  27.2%),  percutaneous
pulmonary  valve  implantation  (PPVI)  (n  =  32,  20.2%)  and  duc-
tus  arteriosus  (DA)  stenting  (n  =  14,  8.9%)  (Fig.  2).  Procedural
indications,  stent  types  and  stent  sizes  are  displayed  in
Table  2.
DA  stenting  was  performed  in  three  patients  with  duct-
dependent  pulmonary  circulation:  pulmonary  atresia  with
intact  ventricular  septum  (n  =  2;  one  patient  requiring  two
stents);  and  tetralogy  of  Fallot  with  pulmonary  atresia
(n  =  1).  In  the  patient  with  tetralogy  of  Fallot  with  pul-
monary  atresia,  a  second  procedure  with  a  second  stent
implantation  in  the  DA  was  required,  2  days  after  the
initial  procedure.  In  the  remaining  10  patients,  the  DA  sten-
ting  was  performed  in  duct-dependent  systemic  circulation
(aortic  arch  interruption,  n  =  5;  hypoplastic  left  heart  com-
plex,  n  =  5)  as  part  of  a  hybrid  strategy.  In  two  cases,  the
DA  stenting  was  performed  during  the  surgery  through  the
main  pulmonary  artery.  In  eight  cases,  the  DA  stenting  was
attempted  via  a  venous  femoral  access  (Fig.  2);  in  one  of
these  cases,  conversion  to  a  transpulmonary  artery  approach
was  required.
More  than  one  stent  was  implanted  in  41  (25.9%)  proce-
dures  (two  stents,  n  =  35;  three  stents,  n  =  3;  four  stents,
n  =  2;  ﬁve  stents,  n  =  1).  A  percutaneous  tricuspid  valve
implantation  required  four  stents  as  a  landing  zone  to  anchor
an  Edwards  SAPIENTM valve  (Edwards  Lifesciences,  Irvine,
i
A
l
iA,  USA)  as  a  rescue  to  stabilize  an  embolized  device.  Dur-
ng  PPVI  procedures,  prestenting  of  the  landing  zone  was
erformed  in  22/28  (78.6%)  patients,  with  one  stent  (n  =  19)
r  two  stents  (n  =  2).  One  PPVI  procedure  required  implan-
ation  of  three  non-covered  stents  to  seal  a  right  ventricular
utﬂow  tract  (RVOT)  tear  before  implantation  of  a  Melody®
alve  (Medtronic  Inc.,  Minneapolis,  MN,  USA).
The  most  implanted  stent  was  the  CP  StentTM (n  =  61,
9.5%)  (Cheatham-Platinum  8-Zig;  NuMED  Inc.,  Hopkinton,
Y,  USA),  followed  by  the  MaxTM LD  stent  (n  =  43,  20.8%)
eV3  Inc.,  Plymouth,  MN,  USA)  and  the  Valeo® stent  (n  =  28,
3.5%)  (Bard  Peripheral  Vascular,  Tempe,  AZ,  USA).  Biore-
orbable  coronary  stents  were  used  in  two  cases  to  treat
roximal  coronary  artery  stenosis.  Covered  stents  were  used
n  17  (8.2%)  cases,  mostly  in  native  aortic  coarctation  (n  =  7)
r  recoarctation  (n  =  3).  Premounted  stents  were  used  in  67
ases  (32.4%).  Stent  types,  sizes  and  indications  are  detailed
n  Table  2.  The  CP  StentTM and  the  MaxTM LD  stent  were  used
n  similar  indications.  The  CP  StentTM was  designed  for  use
n  CHD  and  was  chosen  mainly  for  its  radial  strength.  Alter-
atively,  the  MaxTM LD  stent,  which  has  good  radial  strength
nd  an  open-cell  design,  was  used  when  side  branch  jailing
as  necessary.  The  Valeo® stent  was  particularly  used  dur-
ng  PA  stenting  in  medium-sized  vessels,  given  its  open-cell
esign  and  its  ability  to  be  redilated  to  large  diameters.
tent implantation: technical aspects
tent  implantation  was  performed  according  to  operator
abits.  Overall,  interoperator  stenting  techniques  were  sim-
lar.  Heparin  and  antibiotics  were  used  during  the  procedure.
spirin  was  given  for  a variable  duration  depending  on  stent
ocation  (from  3  months  for  aortic  coarctation  to  ≥  6 months
n  valved  stents).  A  delivering  sheath  was  always  used  for
654  S. Hascoët  et  al.
Table  2  Stent  types,  sizes  and  indications.
Stents  (n  =  207)  Number  (%)  Implantation
ﬁnal  diameter
(mm)
Indications  Stent-related
adverse  event
rate  (95%  CI)
Extra-extra-large  stents
Valiant® thoracic
(self-expandable)a
1  (0.5)  34  Potts  shunt  occlusion
(n  =  1)
0.0 (0.0—97.5)
Sinus-XL  34—60  mmb 1  (0.5)  29  PTVI  landing  zone  (n  =  1)  0.0  (0.0—97.5)
Large  and  extra-large  stents
CP  StentTMc 61  (29.5)m 8—28 PPVI  landing  zone
(n  =  13),  PTVI  landing
zone  (n  =  1),  native
coarctation  (n  =  17),
aortic  recoarctation
(n  =  12),  PA  stenosis
(n  =  13),  cavopulmonary
conduit  fenestration
occlusion  (n  =  2),  RV-to-PA
conduit  (n  =  2),  superior
vena  cava  stenosis  (n  =  1)
8.2  (2.7—18.1)
MaxTM LDd 43  (20.8)  12—28  PPVI  landing  zone  (n  =  16)
PTVI  landing  zone  (n  =  1),
native  coarctation
(n  =  8),  aortic
recoarctation  (n  =  1),  PA
stenosis  (n  =  12),
cavopulmonary  conduit
stenosis  (n  =  1),  RV-to-PA
conduit  (n  =  3),  Mustard
bafﬂe  stenosis  (n  =  1)
4.7 (0.6—15.8)
Advanta  V12TM (covered)e 6  (2.9)  10—20  Native  aortic  coarctation
(n  =  4)  or  aortic
recoarctation  (n  =  2)
0.0 (0.0—45.9)
Protege® GPSTM
(self-expendable)d
1  (0.5)  14  PA  thrombosis  (n  =  1)  0.0  (0.0—97.5)
Medium  stents
Valeo®f 28  (13.5)  5—12  Branch  PA  stenosis
(n =  17),  DA  stenting
(n  =  11)
17.9  (6.1—36.9)
Genesis®g 13  (6.3)  6—15  Branch  PA  stenosis
(n =  10),  BT  shunt
stenosis  (n  =  1),  RV-to-PA
conduit  (n  =  2)
7.7 (0.2—36.0)
Palmaz®g 4  (1.9)  6—26  PPVI  landing  zone  (n  =  2),
RV-to-PA  conduit  stenosis
(n  =  2)
0.0 (0.0—60.2)
Assurant  Cobalt®a 2  (1.0)  6—9  Branch  PA  stenosis  (n  =  2)  0.0  (0.0—84.2)
Omnilink  Elite®h 1  (0.5)  9  Branch  PA  stenosis  (n  =  1)  0.0  (0.0—97.5)
Sinus-SuperFlex
(self-expandable)b
1  (0.5)  7  PA  thrombosis  (n  =  1)  0.0  (0.0—97.5)
Small  stents
Coronary  stents
(bioresorbable,  n  =  2)i
13  (6.3)  2.25—6  DA  stenting  (n  =  6),
branch  PA  stenosis
(n =  2),  coronary  artery
stenosis  (n  =  4),  BT  shunt
thrombosis  (n  =  1)
7.7  (0.2—36.0)
FormulaTMj 1  (0.5)  4  Branch  PA  stenosis  (n  =  1)  0.0  (0.0—97.5)
Dynamic  renalk 1  (0.5)  6  BT  shunt  thrombosis
(n  =  1)
0.0 (0.0—97.5)
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Table  2  (Continued)
Stents  (n  =  207)  Number  (%)  Implantation
ﬁnal  diameter
(mm)
Indications  Stent-related
adverse  event
rate  (95%  CI)
Valved  stents
Melody® valvea 16  (7.7) 18—22 PPVI  (n  =  16) 0.0  (0.0—20.6)
Edwards  SAPIENTM valvel 14  (6.8) 16—29 PPVI  (n  =  13),  PTVI  (n  =  1) 14.3  (1.8—42.8)
BT: Blalock-Taussig; CI: conﬁdence interval; DA: ductus arteriosus; PA: pulmonary artery; PPVI: percutaneous pulmonary valve
implantation; PTVI: percutaneous tricuspid valve implantation; RV: right ventricle.
a Medtronic Inc., Minneapolis, MN, USA.
b Optimed, Ettlingen, Germany.
c Cheatham-Platinum 8-Zig; NuMED Inc., Hopkinton, NY, USA.
d eV3 Inc., Plymouth, MN, USA.
e Atrium Medical Corporation, Hudson, NH, USA.
f Bard Peripheral Vascular, Tempe, AZ, USA.
g Johnson & Johnson Interventional Systems, Warren, NJ, USA.
h Abbott Vascular, Abbott Park, IL, USA.
i Jostent® covered stent (Abbott Vascular, Abbott Park, IL, USA) (n = 1); Absorb bioresorbable stent (Abbott Vascular, Abbott Park, IL,
USA) (n = 2).
j Cook Europe, Bjaeverskov, Denmark.
k Biotronik, Berlin, Germany.
l Edwards Lifesciences LLC, Irvine, CA, USA.
m Nine covered.
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simplantation  of  medium  to  extra-extra-large  stents.  In  small
stents,  a  guiding  catheter  was  used.  In  DA  stenting  the  stent
was  forwarded  on  the  guidewire  only.  A  BIB® balloon  (NuMED
Inc.,  Hopkinton,  NY,  USA)  was  used  for  large  to  extra-large
stents.  A  Z-MEDTM balloon  (NuMED  Inc.)  was  used  for  non-
premounted  medium  stents.  Minor  variations  were  observed
regarding  the  crimping  technique  of  non-premounted  stents.
Success rate/adverse events
Procedures  were  considered  successful  in  96.8%  of  cases
(n  =  153,  95%  CI  92.8—99.0%).  Among  failed  procedures,
stenting  indications  were  native  aortic  coarctation  stenting
(n  =  1;  stent  migration),  RVOT  stenting  (n  =  1;  stent  migra-
tion),  PPVI  (n  =  1;  inability  of  the  Edwards  valve  to  reach  the
landing  zone,  surgical  extraction  through  the  femoral  vein)
and  DA  stenting  (n  =  2:  stent  migration  in  one  case;  stent
blocked  in  the  tricuspid  valve  in  the  other  case).  The  proce-
dural  success  rate  across  centres  ranged  between  90.0%  and
100.0%  and  was  not  signiﬁcantly  different  (P  =  0.3).
Adverse  events  were  observed  in  23  procedures  (14.7%,
95%  CI  9.5—21.0%).  High-severity  adverse  events  were
observed  in  19  procedures  (12.0%,  95%  CI  7.4—18.1%),  while
stent-related  adverse  events  were  observed  in  16  pro-
cedures  (10.1%,  95%  CI  5.9—15.9).  Early  adverse  events
distribution  is  detailed  in  Table  3.  Only  one  arrhyth-
mia  was  reported  in  an  11-year-old  patient  with  truncus
arteriosus  who  had  ventricular  ﬁbrillation  a  few  hours
after  successful  right  ventricle-to-pulmonary  artery  conduit
stenting,  and  was  successfully  deﬁbrillated.  Surgical  extrac-
tion  of  the  stent  was  performed  with  surgical  valved
conduit  replacement  and  pericardial  deﬁbrillator  implan-
tation.  A  cerebellum  stroke  with  spontaneous  complete
recovery  was  observed  in  a  43-year-old  patient  following
native  aortic  coarctation  stenting  with  a  MaxTM LD  stent.
i
a
(
cnother  stroke  was  observed  in  a  13-year-old  patient  fol-
owing  native  transverse  aortic  arch  stenting  with  a  MaxTM
D  stent,  and  was  successfully  treated  by  interventional
hrombectomy.  Early  bacteraemia  (Staphylococcus  aureus)
as  observed  in  a 33-year-old  patient  a  few  days  after  a
PVI  using  an  Edwards  SAPIENTM valve,  leading  to  surgical
ulmonary  valve  replacement.  No  early  stent  fracture  was
eported.
Periprocedural  mortality  was  1.3%  (95%  CI  0.2—4.5%).  A
9-day-old  baby  with  hypoplastic  left  heart  syndrome  under-
ent  DA  stenting  via  a  venous  femoral  approach.  The  Valeo®
tent  that  was  planned  to  be  implanted  was  blocked  in
he  tricuspid  valve  and  could  not  be  advanced  over  the
uidewire  to  the  DA.  Surgical  removal  of  the  stent  was  then
erformed  under  extracorporeal  circulation,  and  DA  sten-
ing  was  subsequently  performed  through  the  pulmonary
rtery.  The  hybrid  procedure  was  completed  but  the  baby
ied  a few  days  later  from  multi-organ  failure.  A  second
eath  was  observed  in  a  22-year-old  patient  as  a  result  of
n  acute  massive  pulmonary  haemorrhage  following  a  PPVI
rocedure.
Two  of  the  ﬁve  failed  procedures  were  associated
ith  high-severity  adverse  events  needing  surgery.  Access-
elated  adverse  events  were  observed  in  six  cases  (26.1%,
5%  CI  6.2—48.4%).
Adverse  events  were  managed  by  stent  implantation  in
ix  cases  (26.1%;  DA  stent  malposition,  n  =  2;  pulmonary
aemorrhage,  n  = 2;  RVOT  tear,  n =  1;  RVOT  stent  migration,
 =  1).  Three  cases  of  acute  reperfusion  lung  syndrome  were
anaged  by  prolonged  mechanical  ventilation.  An  ischaemic
troke  and  a  retroperitoneal  hemorrhage  required  radio
ntervention  (8.7%).  Peripheral  vascular  surgery  for  femoral
ccess-related  adverse  events  was  performed  in  four  cases
17.4%;  aortic  stenting,  n  =  2;  PPVI,  n  =  2).  Emergency
ardiac  surgery  was  required  in  one  case  (4.3%;  DA
656  S. Hascoët  et  al.
Figure 1. An unusual indication for stent implantation: Potts shunt occlusion. A. Angiography of the left pulmonary artery (LPA); the
descending aorta (Ao) is made opaque through the Potts shunt. B. Simultaneous angiography of the LPA and aorta before implantation of a
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Saliant® thoracic covered stent graft (Medtronic Inc., Minneapolis, 
ilation. D. Angiography of the LPA after stent implantation; no res
tenting  with  stent  blocked  in  the  tricuspid  valve).  Urgent
ardiac  surgery  was  also  performed  in  two  cases  (bacter-
emia  following  PPVI,  n  =  1;  ventricular  ﬁbrillation  following
VOT  stenting,  n  =  1).  Haemodynamic  instability  following
A  stenting  was  managed  medically  in  two  cases.
Stent-related  adverse  event  distribution  was  not  signif-
cantly  different  regarding  stent  type  (P  =  0.80)  (Table  2).
he  distributions  of  total  adverse  events,  stent-related
dverse  events  and  high-severity  adverse  events  were  not
igniﬁcantly  different  across  centres  (P  =  0.24,  P  =  0.44  and
 =  0.31,  respectively).  For  indications  with  more  than  10
rocedures,  total  adverse  event  rates  ranged  from  10.0%
95%  CI  2.5—44.5%)  for  RVOT  stenting  to  28.6%  (95%  CI
.4—58.1%)  for  DA  stenting.  DA  stenting  adverse  events
ccurred  in  four  cases,  all  in  duct-dependent  systemic
irculation.  No  adverse  events  were  reported  in  DA  sten-
ing  of  duct-dependent  pulmonary  circulation.  Distribution
f  stent-related  adverse  events  was  signiﬁcantly  differ-
nt  across  procedures,  considering  transcatheter  pulmonary
alve  implantation,  DA  stenting,  PA  stenting  and  pooled
ther  procedures  (P  =  0.028).  Potential  risk  markers  of
h
I
rSA). C. Angiography of the aorta after stent implantation and post
 shunting is seen.
dverse  events  are  reported  in  Table  4. Only  stent  size
nd  procedure  type  were  signiﬁcantly  associated  with  stent-
elated  adverse  events  after  logistic  regression  analysis.
A  stenting  (OR  12.4,  95%  CI  2.0—77.5;  P  <  0.01)  and  PPVI
OR  5.9,  95%  CI  1.1—32.3;  P  =  0.04)  remained  associated
ith  an  increased  risk  of  stent-related  adverse  events  after
djustment  for  the  operator.  DA  stenting,  while  represent-
ng  8.9%  of  procedure  indications,  accounted  for  25.0%  of
rocedures  with  stent-related  adverse  events.  Centre,  oper-
tor,  age,  weight,  genetic  syndrome  and  type  of  stent  were
ot  signiﬁcantly  associated  with  an  increased  risk  of  adverse
vents.
iscussion
afety and efﬁcacy of stenting in congenital
eart disease
n  this  retrospective  multicentre  observational  study,  we
eport  the  use  of  stenting  in  CHD  across  11  French  centres.
Stenting  in  congenital  heart  diseases  657
Figure 2. Ductus arteriosus (DA) stenting. A. Angiography of the DA through a retrograde approach. B. From a venous femoral access, a
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tballoon-expandable Valeo® stent (Bard Peripheral Vascular, Tempe, 
result.
We  observed  that  in  the  current  congenital  interventional
cardiology  era,  stents  are  used  routinely  in  a  wide  range
of  settings,  from  neonates  to  adult  patients  [16,17].  Sten-
ting  in  CHD  is  a  highly  successful  procedure  (over  95%
success  rate  in  this  study),  regardless  of  implantation  site,
type  of  stent  and  complexity  of  procedure.  However,  early
complications  are  frequent.  Particularly,  in  our  study,  when
looking  at  determinants  of  complications,  we  observed  that
DA  stenting  and  PPVI  were  associated  with  an  increased
risk  of  stent-related  adverse  events.  Thus,  the  rate  of
complications  is  highly  dependent  on  the  location  of  stenting
[18].  PPVI,  using  the  two  currently  available  devices  (i.e.  the
Melody  valve  and  the  Edwards  SAPIENTM valve),  has  become
a  routinely  performed  procedure  [19,20]. However,  it  is  a
long  procedure  that  often  requires  prestenting  of  the  landing
zone  to  strengthen  the  RVOT,  which  can  lead  to  an  increased
rate  of  adverse  events,  as  observed  in  our  study  [21].  While
representing  10%  of  procedures  in  this  study,  DA  stenting  is
also  one  of  the  most  challenging  interventions,  accounting
for  25%  of  all  procedures  with  stent-related  complications.
A  hybrid  stage  1  palliation  programme  was  only  recently
started  in  one  centre.  A  learning  curve  effect  may  explain
why  these  results  compared  unfavourably  with  other  reports
[22].Few  stent  implantation  failures  were  related  to  stent
malpositioning,  stent  embolization  or  an  inability  to  dis-
patch  the  stent  (3.2%  of  all  implantations).  This  is  less  than
the  7.7%  ratio  previously  reported  by  Van  Gameren  et  al.
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tSA) is positioned across the DA. C. The stent is implanted. D. Final
n  2006  in  a  Dutch  and  Belgian  study  with  a  similar  design,
overing  the  ﬁrst  10  years  of  stent  use  in  CHD  [18].  Despite
mproved  experience,  stent  implantations  remain  challeng-
ng  procedures,  and  operator  skill  is  still  a  key  issue  [23].
he  rate  of  early  complications  remains  high  (14.7%  of  pro-
edures  in  this  study,  19%  in  the  study  by  Van  Gameren
t  al.),  leading  to  an  overall  procedural  mortality  of  1.3%
n  our  work.  Most  complications  during  stent  implantation
ere  transient  and  resolved  without  ending  the  procedure;
ome  others  required  emergency  surgery  [24].  Thus,  our
ork  reminds  us  that  catheterization  of  CHD  with  stent
mplantation  should  be  performed  in  specialized  centres
ith  congenital  cardiac  surgery  available  as  backup  [25].
ifferent types of stents
ur  study  conﬁrms  the  important  role  of  the  CP  Stent,  which
as  developed  speciﬁcally  for  the  treatment  of  CHD  [26,27].
onversely,  the  role  of  the  MaxTM LD  stent  is  described  less
requently  in  the  literature.  Our  study  reports  the  efﬁciency
nd  the  safety  of  this  stent  as  an  alternative  to  the  CP
tent  for  use  in  various  congenital  heart  lesions.  However,
wo  strokes  were  observed  during  aortic  arch  coarctation
tenting  with  this  stent.  Despite  the  open-cell  design,  the
harp  edges  or  potential  thrombogenicity  may  have  con-
ributed  to  these  adverse  events.  Our  study  also  illustrates
he  increased  impact  of  the  Valeo® stent,  mostly  used  in
658  S. Hascoët  et  al.
Table  3  Description  of  early  adverse  events.
Procedures  (n  =  158)  %  95%  CI
Adverse  events  23  14.7  9.5—21.0
Level  1  2  1.3
Level  2  2  1.3
Level  3  5  3.2
Level  4  12  7.6
Level  5 2 1.3
Stent-related  adverse  events 16 10.1 5.9—15.9
High-severity  adverse  events 19 12.0 7.4—18.1
Adverse  event  details
Stroke  2  1.3  0.2—4.5
Haemothorax  2  1.3  0.2—4.5
Intra-lobar  pulmonary  haemorrhage  1  0.6  0.0—3.5
Reperfusion  pulmonary  oedema  2  1.3  0.2—4.5
PA  dissection  1  0.6  0.0—3.5
Ventricular  arrhythmia  1  0.6  0.0—3.5
Bacteraemia  1  0.6  0.0—3.5
Groin  haematoma  (managed  medically)  2  1.3  0.2—4.5
Groin  haematoma  (managed  surgically)  2  1.3  0.2—4.5
Retroperitoneal  haemorrhage  1  0.6  0.0—3.5
Femoral  arteriovenous  ﬁstula  1  1.3  0.0—3.5
Transient  stent  thrombosis  1  0.6  0.0—3.5
Haemodynamic  instability  (DA  stenting)  2  1.3  0.2—4.5
Stent  migration  3  1.9  0.4—5.4
Stent  malposition  (surgical  extraction)  2  1.3  0.2—4.5
Death  2  1.3  0.2—4.5
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lCI: conﬁdence interval; DA: ductus arteriosus; PA: pulmonary arte
he  peripheral  pulmonary  artery  stenting  and  in  DA  stenting
10,28].
Bare-metal  coronary  stent  implantation  has  been
equired  occasionally  in  children,  but  the  inability  to  follow
essel  growth  has  been  a  major  issue  [29].  In  this  study,
ioresorbable  coronary  stents  were  used  in  two  children
ith  post-operative  coronary  stenosis.  Bioresorbable  stents
ave  been  developed  recently  for  coronary  artery  diseases,
ith  the  aim  of  dissolving  after  vessel  healing.  This  concept
s  particularly  interesting  in  children.  Indeed,  once  the  stent
as  disappeared,  the  vessel  may  follow  the  child’s  growth,
bviating  the  need  for  future  surgery  or  dilation  [30,31].
owever,  radial  force  is  low  and  only  small  stent  diameters
re  currently  available.  Bioresorbable  stents  dedicated  for
se  in  CHD  are  under  development,  and  efﬁciency  in  children
emains  to  be  demonstrated  [32].
Covered  stents  were  used  in  fewer  than  10%  of  proce-
ures,  mainly  in  ﬁrst  intention,  to  treat  more  complex  or
ighter  native  aortic  coarctation  or  post-operative  recoarc-
ation  [33].  Covered  stents  were  also  used  occasionally  to
losed  shunt  patency  (Potts  fenestration  [34]  and  cavopul-
onary  conduit  fenestration  occlusion  [35]) or  to  seal
amaged  vessels  after  pulmonary  artery  or  RVOT  angio-
lasty.  In  our  series,  the  covered  CP  Stent  was  mostly  used.
owever,  the  outer  polytetraﬂuoroethylene  membrane  of
his  device  is  fragile  and  can  easily  be  damaged  during  stent
rimping  or  stent  insertion  into  the  delivery  sheath.  Thus,
he  proﬁle  is  higher  and  large  sheaths  are  needed,  which
ay  be  a  point  of  concern  in  small  children.  In  our  work
nd  that  of  others,  the  Advanta  V12TM stent  (Atrium  Medical
m
o
c
porporation,  Hudson,  NH,  USA)  was  used  as  an  alternative
n  aortic  (re)coarctation  stenting  [36].  This  stent  has  a  bet-
er  proﬁle  because  its  membrane  is  completely  incorporated
nto  the  inner  and  outer  parts  of  a  premounted  balloon-
xpandable  stent.  On  the  other  hand,  radial  strength  seems
ower  and  collapse  has  been  observed  [37].  The  ideal  cov-
red  stent  for  use  in  CHD  remains  to  be  developed.  The
volution  of  stent  framework  and  materials,  and  new  syn-
hetic  and  biological  membrane  components  may  help  to
vercome  these  issues  [38].
tudy limitations
ur  work  has  several  limitations.  Given  the  retrospective
esign  of  this  study,  although  an  effort  has  been  made  to
eport  all  adverse  events,  it  is  likely  that  some  adverse
vents,  especially  those  of  lesser  signiﬁcance  (levels  1  to  2),
ay  have  not  been  reported  completely.  Our  study  may  also
ot  have  enough  power  to  identify  all  risk  markers  of  adverse
vents.  Nevertheless,  we  identiﬁed  that  the  type  of  stenting
rocedure  was  a  key  issue.  Moreover  we  did  not  study  the
ollow-up,  so  we  were  unable  to  provide  data  on  medium-
nd  long-term  late  adverse  events,  such  as  stent  fractures,
tent  restenosis,  vessel  aneurysm  and  stent  mismatch  fol-
owing  children  growth.  This  work  has,  nevertheless,  the
erit  to  be  a  preliminary  work  of  a  collaborative  group
f  experts  that  was  recently  set  up  with  the  objective  of
reating  a  French  prospective  database  of  catheterization
rocedures  in  the  ﬁeld  of  CHD  to  overcome  these  limits.
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Table  4  Potential  risk  markers  of  adverse  events  after  stenting.
Procedural  adverse  events  Stent-related  adverse  events  High-severity  adverse  events
OR  (95%  CI) P  OR  (95%  CI) P  OR  (95%  CI)  P
Operator  0.11  0.15  0.19
Centre  0.12 0.14 0.15
Age  (per  year) 0.99  (0.96—1.02) 0.53 1.00  (0.96—1.03) 0.90  1.00  (0.97—1.04)  0.90
≥  1  to  <  15  years 1  1 1
<  1  year  1.49  (0.41—5.45)  0.55  2.87  (0.69—11.88)  0.15  0.89  (0.17—4.64)  0.88
≥  15  years  1.04  (0.39—2.74)  0.94  1.55  (0.48—5.00)  0.46  1.38  (0.49—3.87)  0.54
Weight  (per  10  kg)  0.97  (0.82—1.14)  0.69  0.98  (0.81—1.18)  0.83  1.08  (0.90—1.30)  0.42
Genetic  syndrome  0.76  (0.09—6.46)  0.80  1.11  (0.13—9.69)  0.922  0.97  (0.11—8.35)  0.97
Stent  type  0.28  0.79  0.49
Valved  stent  1.07  (0.22—5.19)  0.93  1.70  (0.34—8.46)  0.52  1.37  (0.28—6.71)  0.70
Covered  stent  0.39  (0.05—3.14)  0.38  0.37a 0.50  (0.06—4.00)  0.51
Premounted  stent  1.12  (0.43—2.93)  0.22  1.58  (0.54—4.65)  0.40  0.64  (0.20—2.04)  0.45
Self-expandable  stent  1.0a 1.0a 1.0a
Stent  size
Large  1  1 1
Medium  1.47  (0.30—7.12)  0.63  6.26  (0.62—63.52)  0.12  2.00  (0.37—10.70)  0.42
Small  3.21  (0.82—12.61)  0.09  10.91  (1.20—99.00)  0.03b 1.92  (0.36—10.23)  0.45
Extra-large  2.39  (0.65—8.83)  0.19  5.33  (0.57—49.77)  0.14  3.25  (0.78—13.52)  0.10
Extra-extra-large  5.62  (0.41—76.43)  0.19  24.00  (1.07—539.11)  0.04b 7.67  (0.53—110.65)  0.13
Procedure  type  0.28a 0.01a,b 0.5a
Other  procedures  1  1 1
DA  stenting  3.37  (0.83—13.67)  0.09  12.80  (2.07—79.28)  0.01b 1.67  (0.30—9.27)  0.56
PPVI  1.95  (0.60—6.36)  0.27  5.93  (1.08—32.45)  0.04b 2.31  (0.68—7.83)  0.18
PA  stenting  1.26  (0.40—4.04)  0.69  3.90  (0.73—21.07)  0.11  1.22  (0.35—4.26)  0.76
Procedure  typec
Other  procedures  1  1 1
DA  stenting  3.26  (0.80—13.30)  0.10  12.44  (2.00—77.46)  0.01b 1.61  (0.29—9.02)  0.59
PPVI  1.93  (0.59—6.31)  0.28  5.89  (1.07—32.27)  0.04b 2.29  (0.67—7.78)  0.18
PA  stenting  1.24  (0.39—3.99)  0.71  3.85  (0.71—20.81)  0.12  1.20  (0.34—4.20)  0.78
CI: conﬁdence interval; DA: ductus arteriosus; OR: odds ratio; PA: pulmonary artery; PPVI: percutaneous pulmonary valve implantation.
a Fisher’s exact test.
b P value < 0.05.
D
T
o
Rc After adjustment for operator.
Conclusions
Stents  are  useful  in  various  CHD  catheterization  procedures,
from  infancy  to  adult  age.  The  adverse  events  rate  should
still  not  be  underestimated  and  is  mainly  related  to  the  type
of  procedure.  Ideal  stents  for  use  in  CHD  remain  to  be  devel-
oped.  Miniaturization  of  delivery  systems  would  facilitate
implantation  in  tortuous  and  small  vessels,  and  decrease
the  risk  of  vessel  access  trauma.  Biodegradable  stents  may
overcome  the  inability  of  stents  to  follow  natural  vessel
growth.  There  is  now  a  wide  panel  of  stents  used  in  CHD.
Further  development,  comparative  studies  and  certiﬁcation
procedures  have  to  be  encouraged.
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